secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016846
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Q2 2022: Net loss $16.2M, cash $306.8M; positive Phase 2 lupus nephritis data
--------------------------------------------------------------------------------

- Positive MISSION Phase 2 topline: 64.7% ORR, 35.2% CRR in lupus nephritis patients.
- Cash, cash equivalents and marketable securities totaled $306.8M as of June 30, 2022 (up from $208.4M year-end 2021).
- Net loss for Q2 2022 was $16.2M ($0.25 per share) vs $13.0M in Q2 2021.
- Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer in July 2022.
- R&D expenses $11.3M (+$2.0M YoY); G&A $5.0M (+$1.3M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022016846/0000950170-22-016846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022016846/kzr-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer